Michele Laurel

Michele Laurel has over 15 years of experience in clinical quality assurance and regulatory compliance. Michele currently serves as the Executive Director of Clinical QA at Jasper Therapeutics. Prior to this role, they worked as the Executive Director of Clinical QA at Cortexyme, Inc., where they built infrastructure around ICH/GCP Inspection Readiness. Michele also served as the CQA Project Lead at Vertex Pharmaceuticals and as the Director of Clinical Quality Assurance at Sangamo Therapeutics, Inc. In their previous positions, they held roles such as Senior Manager of GCP Compliance at Theravance Biopharma US, Inc. and Senior Auditing Specialist at Clinical Auditing Network. Michele has extensive experience managing clinical research studies, conducting procedural gap analyses, and ensuring compliance with ICH/GCP Guidance and regulations.

Michele Laurel holds a Bachelor's degree in Zoology/Animal Biology from The University of Texas at Austin, earned between 1982 and 1986. Michele further pursued their education at the same university, obtaining a Master's degree in Biochemistry and Molecular Biology. Michele has also completed substantial coursework towards a Doctor of Philosophy (Ph.D.) in Molecular Biology, although the status of their degree is listed as ABD (all but dissertation).